Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real-world Prospective Cohort Study of Patients With Moderate to Severe Acne Vulgaris Treated With Sarecycline (Seysara®) In Community Practice Settings in the U.S

Next Previous
X
Search
Trial Profile

A Real-world Prospective Cohort Study of Patients With Moderate to Severe Acne Vulgaris Treated With Sarecycline (Seysara®) In Community Practice Settings in the U.S

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarecycline (Primary)
  • Indications Acne vulgaris
  • Focus Therapeutic Use
  • Acronyms PROSES
  • Sponsors Almirall S.A.

    • Most Recent Events

    • 12 Mar 2024 Results of Safety of sarecycline presented at the American Academy of Dermatology annual Meeting 2024
    • 21 Mar 2023 Results evaluating facial IGA and the associated IGA success, stratified by race and baseline AV severity, among AV patients administered sarecycline in community practices across the U.S, presented at the American Academy of Dermatology annual Meeting 2023
    • 21 Oct 2022 According to an Almirall media release, data from this study will be publishing in a peer-reviewed journal by the end of this year 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top